On September 27th, 2024, the FDA approved Sanofi/Regeneron's Dupixent® (dupilumab) for use as an add-on maintenance treatment of adults who have inadequately controlled chronic obstructive pulmonary disease (COPD) and eosinophilic phenotype. In clinical trials,…
On October 2, 2024, the Food and Drug Administration (FDA) announced that it removed tirzepatide injection, a glucagon-like peptide 1 receptor agonist (GLP-1 RA) marketed by Eli Lilly, from its drug shortages list. Tirzepatide is the…
On September 20th, 2024, the U.S. Food and Drug Administration (FDA) approved MedImmune and AstraZeneca's FluMist® (influenza virus vaccine) for self-administration. FluMist® is…
In the first quarter of 2024, The American Society of Health-System Pharmacists (ASHP) reported an estimated 323 active drug shortages, slightly exceeding the previous record of 320 shortages set in 2014. In light of…
The rapidly growing popularity of glucagon-like peptide 1 (GLP-1) receptor agonists for use in weight loss has led to widespread shortages of…
